Clinical Trial Update: Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating hALK.CAR T cells in children with relapsed or refractory high-risk neuroblastoma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• hALK.CAR T Cells

Snippet

Sponsor: Roberto Chiarle | Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1, Phase 2 | Status: RECRUITING